Jun 11, 2020 / 08:40PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. We will continue with the next session. Good afternoon, everyone, and thanks for hanging up -- hanging in with us here at the Goldman Sachs Healthcare Conference. I'm Paul Choi, the SMID-cap Biotechnology analyst here at GS. And we'll continue with our next session, which is Esperion Therapeutics. We're joined from the management today by the CEO, Tim Mayleben. What we'll do here, as with past sessions, is I'll turn it over to Tim for some opening comments. And after that, we'll go into the Q&A.
If along the way, as in past sessions, if any investors have comments or questions, please feel free to submit them via the Goldman Sachs research portal. Or alternatively, you can e-mail questions to me directly. And time permitting at the end, we'll try and squeeze in a question or 2, if we have room for them.
Otherwise, with that, I'll turn it over to Tim for an overview and maybe some opening remarks. Tim?
Timothy Mayleben -
Thank you, Paul. And I want to start out by just
Esperion Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 12, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers